Search Results for: stem cell person of the year

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics

/ / 5 Comments
CRISPR Therapeutics

The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and […]

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »

Can trying to cheat death paradoxically kill you sooner?

/ / 10 Comments
anti-aging, Dorian Gray

Can you paradoxically kill yourself early by trying to cheat Death? For example, die through risky anti-aging approaches? The question came to mind because such longevity efforts have become more extreme. They also get more hype in the media. I’ve been following the anti-aging space mainly because many interventions involve risky stem cell injections. Those

Can trying to cheat death paradoxically kill you sooner? Read More »

Review of Docere Clinics run by Harry Adelson including total-body injections

/ / 2 Comments
Amy Killen, Docere Clinic

In today’s post, I reviewed a stem cell clinic firm called Docere Clinics. In my opinion, there are some concerning issues here and reasons for caution. One type of procedure at Docere is particularly surprising and raises risks in my view. What is Docere Clinics? | What kind of stem cells does Docere use? | What they

Review of Docere Clinics run by Harry Adelson including total-body injections Read More »

Biological age, health flexing, & stabs at rejuvenation

/ / 4 Comments
health flexing, biological age

We all know people who seem far younger than their age, which feeds into the idea of biological age. It’s often in the news these days and all over social media. Some people who are fighting high-profile battles with aging are also doing something I call “health flexing.” I also called these folks by another

Biological age, health flexing, & stabs at rejuvenation Read More »

Is DNA methylation destiny? Diving into new epigenetic clock research

/ / 1 Comment

I’ve been thinking more about the steady stream of epigenetic clock research out there.  How convincing is the research on such clocks? Do they tightly relate to human biological age?  The related notion of turning back such hypothetical clocks to reverse aging is exciting but controversial. It doesn’t help that some are hyping all of

Is DNA methylation destiny? Diving into new epigenetic clock research Read More »

Weekly reads: gene therapy nod, Nature pub ethics, CRISPR LDL

/ / Leave a Comment
Multipotent & totipotent vs pluripotent stem cells, very early human embryos totipotent stem cells

Totipotency literally means all powerful, but it refers in biology to specific cells. These cells can make every type of cell in the body of an organism plus the extraembryonic tissues needed for development. This includes humans. So if you could reprogram human cells like blood or skin cells into totipotent stem cells, you might

Weekly reads: gene therapy nod, Nature pub ethics, CRISPR LDL Read More »

Weekly reads: UC Davis Medical School diversity, CRISPR, Parkinson’s

/ / 2 Comments
UC Davis Medical School

It’s been almost seventeen years that I’ve been a professor here at UC Davis Medical School. It feels like home. I enjoy teaching our first-year medical students each year. Some end up doing research in my lab. Our school recently got a nice write-up over at STAT News by Usha Lee McFarling on the diversity

Weekly reads: UC Davis Medical School diversity, CRISPR, Parkinson’s Read More »

3rd Invitrx warning highlights FDA oversight weakness

/ / 8 Comments

The FDA seems oddly slow in oversight of unproven stem cell clinic-related firms like one here in California called Invitrx Therapeutics. I’ve written before about Invitrx, but interactions between them and the FDA have continued including a new warning letter. It’s become a puzzling situation. More broadly, the FDA has done relatively little in the past

3rd Invitrx warning highlights FDA oversight weakness Read More »